Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proestrene plus interferon vs interferon alone in postmenopausal high-risk cervical HPV infection
ChiCTR2300076672Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of progesterone in human papillomavirus infection (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Effectiveness of different drugs in the treatment of high-risk HPV infection after menopause. Started Aug 2023; status: recruiting.
02
Drugs
progesterone
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR2300076672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076672.